photoaging Polycaprolactone, Facial rejuvenation, Photoaging
Conditions
Interventions
Patients were treated with Solubilized Liquid Polycaprolactone 3 sessions every 4 weeks.
Then they were instructed to follow up at 1, 3, 6, 9 and 12 months after last treatment.
Experimental Drug
Sponsors
Faculty of Medicine Siriraj hospital
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age between 20-60 years, both male and female. 2. Participants who have dark spots, wrinkles, and enlarged pores.
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women. 2. Participants with a history of blood clotting disorders, anemia, liver disease, cancer, or autoimmune diseases. 3. Heavy smoking or drinking 4. Participants with facial dermatitis, wounds, or skin infections. 5. Participants with a history of allergy to anesthetics. 6. Participants who regularly take hormonal medications, contraceptive injections or pills, or NSAIDs. 7. Participants who take medications affecting blood clotting, such as aspirin or anticoagulants. 8. Participants who have undergone facial lifting treatments, including device-based lifting or thread lifting, within 12 months before participating in the study. 9. Participants who have received facial dermal filler injections within 24 months before participating in the study. 10. Participants who have had platelet-rich plasma (PRP) injections on the face within 12 months before participating in the study. 11. Participants who have received botulinum toxin injections on the face within 6 months before participating in the study. 12. Participants who have undergone collagen-stimulating laser treatments on the face, such as picosecond laser, erbium:YAG laser, Fractora, or eMatrix laser, within 12 months before participating in the study. 13. Participants with a history of keloid or hypertrophic scarring. 14. Participants with diagnosed psychiatric disorders. 15. Participants who do not consent to having their photos taken for treatment evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Wrinkles indentation baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9and 12 months after 3rd treatment, Antera,Texture baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9and 12 months after 3rd treatment, Antera | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9and 12 months after 3rd treatment, Adverse events,Skin firmness baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9and 12 months after 3rd treatment, Cutometer,melanin index baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9and 12 months after 3rd treatment, Mexameter,Erythema index baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9and 12 months after 3rd treatment, Mexameter,Hydration baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9and 12 months after 3rd treatment, Corneometer, Individual typology angle (ITA) baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9and 12 months after 3rd treatment, Colorimeter | — |
Countries
Thailand
Contacts
Public ContactRungsima Wanitphakdeedecha
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Outcome results
None listed